ONCOTHEIS

OncoCilAir™

A unique platform to test Oncolytic Viruses against Lung Cancer

Oncolytic virotherapy is an innovative treatment modality which uses replication competent viruses to destroy cancers. A number of oncolytic strategies are rapidly advancing toward clinical use with the requirement to test specificity and safety.

Due to its dual composition (healthy and cancerous human tissues) OncoCilAir™ is an ideal in vitro model for the concurrent testing of the efficacy and the specificity of oncolytic viruses against malignant cells and their non-toxicity against healthy tissues, all in a single culture well.

hyperspectral
x

Typical hyperspectral image of a 3D OncoCilAir™ airway microtissue (blue) with tumor nodules (red) after viral infection (green). Coll. V.Kilin and L.Bonacina, Biophotonics lab, UNIGE.

Mode of Inoculation

Thanks to the unique lifespan of OncoCilAir™ (months), single but also repeated administrations of modified viruses can be performed to simulate chronic treatment in patients.

mimic-airborne-or-systemic-delivery

Assessment of Combined Therapies

OncoCilAir™ allows testing oncolytic therapies in combination with standard chemotherapeutics to detect synergistic improvement of tumor control over monotherapy.

Endpoints

Typical OncoCilAir™ endpoints can be measured throughout the treatment:

In addition, standard protein (immunostaining, western blot) and gene (qPCR, arrays) expression analyses, as well as pathway interference through genetic modifications can be applied to investigate mechanisms of action.


Contract us to evaluate your novel oncolytic virotherapy
Test OncoCilAir™ microtissues in your facility

To learn more about Oncotheis services, please contact us


About OncoCilAir™

OncoCilAir™ is a human microtissue-based 3D lung cancer model which incorporates both a functional airway epithelium and developing tumors.

oncocilair
oncocilair
OncoCilAir™ is cultured at the air-liquid interface on PET Transwell® 0.4 µm inserts and can be kept in culture for several months, allowing the concurrent testing of drug efficacy, side-toxicity and tumor recurrence.
Go to Oncicilair™ Product